MNPR Q1 EPS Forecast Boosted by Brookline Capital Management

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at Brookline Capital Management upped their Q1 2025 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a report released on Wednesday, February 5th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their prior forecast of ($0.78). The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics' Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS and FY2025 earnings at ($3.54) EPS.

Other analysts also recently issued research reports about the company. Piper Sandler initiated coverage on Monopar Therapeutics in a research note on Friday, January 10th. They issued an "overweight" rating and a $72.00 target price on the stock. HC Wainwright upped their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, January 22nd.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock traded down $5.84 during trading hours on Monday, hitting $44.68. 59,080 shares of the stock traded hands, compared to its average volume of 67,258. The firm's 50 day moving average price is $31.08 and its 200-day moving average price is $16.48. The stock has a market capitalization of $272.55 million, a price-to-earnings ratio of -22.68 and a beta of 1.30. Monopar Therapeutics has a 1 year low of $1.65 and a 1 year high of $54.30.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MNPR. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics in the fourth quarter worth approximately $45,000. Geode Capital Management LLC boosted its position in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after buying an additional 24,530 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Monopar Therapeutics during the fourth quarter worth $2,861,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.